Instrument NameSanofi-Aventis S.A. ADRInstrument Symbol(SNY-Q)

Instrument ExchangeNASDAQ

TORONTO , Oct. 28, 2024 /CNW/ - Sanofi is pleased to announce Beyfortus ® (nirsevimab) will be broadly available for babies born in Ontario , Quebec , Nunavut , Northwest Territories , and the Yukon this fall. The administration of this immunization to infants has begun. Beyfortus ® is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. ii As RSV circulates seasonally between November and April, causing a high burden of bronchiolitis, pneumonia and hospitalizations in infants and newborns, this timely availability aims to help safeguard the most vulnerable populations during this critical period. With the ongoing challenges posed by RSV, Sanofi is committed to increasing access to this immunization across Canada .

One of these players has split its stock in the past. The other one hasn't.

No investor can ignore a crushing bottom-line beat and raised profitability guidance.

SNY earnings call for the period ending September 30, 2024.

Let's look beyond this piece of bad news from regulators.

Monday U.S. Economic Lookahead U.S. leading economic indicators (Sept.) Featured Earnings ...

This Nuvation Bio board member and longtime biotech industry insider carried out his first purchase since his appointment in January.

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

/CNW/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection

The biotech continues to earn important wins, but is it enough?

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading market shares in growing categories.

Investors found something to like about the company's recent round of clinical trials for a key pipeline medication.

Don't be too quick to jump on the Wall Street bandwagon.

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), is reporting new preclinical data...

Its been a good year so far for the biotech, but how long can it keep the momentum going?

SNY earnings call for the period ending June 30, 2024.

Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities.

We will know a lot more about the vaccine maker's long-term prospects in 12 months.

Shares of the vaccine maker are trading up 230% this year.

The integration of AI and healthcare is well underway.

These pharma and biotech players could become long-term winners.